Question 1

Has Mark Dickson, MD received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $320,789 in general payments to Mark Dickson, MD across 12 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Mark Dickson, MD did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Mark Dickson, MD come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Eli Lilly	8	$154,359
Sanofi US Services Inc.	1	$76,808
Sumitomo Pharma America, Inc.	2	$65,196
Aadi Bioscience, Inc.	1	$24,426

Drug	Claims	Cost to plans & patients
IbrancePalbociclib	17	$260,083
Oxycodone Hcl	14	$130

Mark Dickson, MD

Payments from drug & device makers

Who reported the general payments

How this compares

Medicare billing

Most prescribed under Part D

Other hematology & oncology in New York